Fundraising FoxPsy Therapeutics
Boston, US · Delaware corporation · 2 known investors
Find your way into Psy Therapeutics
Sign up to see every warm intro you have to Psy Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Psy Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Innovative drug discovery platform for the treatment of CNS disorders
Founders & leadership
DS
David S. BarlowExecutiveDavid S. Barlow is an executive with experience in specialty biopharmaceuticals and healthcare, having led teams through startup commercialization, capital raises, and IPO processes. He has worked in strategic planning, government affairs, reimbursement, sales, marketing, and business development.
WW
JT
Jeff TrodermanExecutive
BR
Bryan RobertsNamed on SEC filing
BB
Brant BinderNamed on SEC filing
Board
PM
Paul MurphyBoard director
AC
Alan CrossBoard director
JF
Jerry F. RosenbaumBoard director
DW
Daniel Weiss PickBoard director
Investors · 2
Palo Santo VClisted by Palo Santo VC
How we know: Palo Santo VC's portfolio page · Not right? Tell us
.jpeg){kind=logo}
B Capital GroupreportedSan Francisco · $10M – $50M
How we know: a partner's Signal profile · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$10.7M disclosed across 2 of 3 rounds · 2019–2024
▶$6.8MraisedSep 2025 · 23 investors · PharmaceuticalsRule 506(b)
▶$6.8MraisedSep 2025 · 23 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- David S. BarlowExecutive Officer, Director
- Paul MurphyDirector
- Alan CrossDirector
- William WagnerExecutive Officer
- Jerry F. RosenbaumDirector
- Daniel Weiss PickDirector
- Jeff TrodermanExecutive Officer
- Offering amount
- $20.4M
- Amount sold
- $6.8M
- First sale
- Dec 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$4MraisedOct 2019 · 19 investors · Other Health CareRule 506(b)
▶$4MraisedOct 2019 · 19 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Bryan RobertsDirector
- David S. BarlowExecutive Officer, Director
- Alan CrossExecutive Officer
- Daniel Weiss PickDirector
- Brant BinderExecutive Officer, Director
- Offering amount
- $4.3M
- Amount sold
- $4M
- First sale
- Sep 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Psy Therapeutics do?
- Innovative drug discovery platform for the treatment of CNS disorders
- Who are Psy Therapeutics's investors?
- Psy Therapeutics's investors include Palo Santo VC, B Capital Group.
- How much funding has Psy Therapeutics raised?
- Psy Therapeutics has disclosed $10.7M raised across 2 of its 3 known rounds.
- Where is Psy Therapeutics headquartered?
- Psy Therapeutics is headquartered in Boston, US.